Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas

Abstract

The presence of human thyroglobulin (HTg) in serum of patients with differentiated thyroid carcinoma was studied. The thyroglobulin detected in the serum of such patients was identical by immunological criteria to the serum standard used in the radioimmunoassay. The serum thyroglobulin levels in untreated patients with differentiated thyroid carcinoma ranged from 22.0 to 445.0 ng/ml with a mean of 144.3 ± 46.5 ng/ml (SEM) (n = 10). The mean serum thyroglobulin measured postoperatively in 7 of these patients was 6.4 ± 1.5 ng/ml, not statistically different from the mean level of 5.1 ± 0.49 ng/ml (range 0-20.7 ng/ml) observed in 71 out of 95 control subjects with detectable HTg levels. By contrast serum HTg levels were normal or undetectable in subjects with medullary carcinoma of the thyroid. HTg levels were within normal limits in sera of patients who had previously undergone successful therapy for a differentiated thyroid carcinoma and in whom no metastases could be documented. The mean level for this group was 4.9 ± 0.51 ng/ml (n = 43). In contrast, patients with documented metastases had a mean serum thyroglobulin level of 464.9 ± 155.6 ng/ml (n = 6). The data support the thesis that in differentiated thyroid carcinoma serum thyroglobulin levels are elevated when metastases develop after initial treatment. It is proposed that the measurement of thyroglobulin in the serum represents a simple and valuable adjunct in the posttreatment follow up of patients with differentiated thyroid cancer.